The incidence of EGFR Ex20ins mutations in ISP and ISP-associated SNSCC tumours implicates a prominent role for activating EGFR mutations in these diseases and opens up an exciting opportunity for treatment with EGFR targeted therapies. The gene discussed is EGFR; the disease is neoplasm.